Connect Biopharma Insider Buying: Panacea Venture Adds 1.16M Shares
Director James Huang and Panacea Venture bought 1.16 million shares of Connect Biopharma at $3.45, boosting their stake to 21.2%.
/ 2 items
Director James Huang and Panacea Venture bought 1.16 million shares of Connect Biopharma at $3.45, boosting their stake to 21.2%.
Roth Capital starts coverage on HeartBeam (BEAT) with a $4 target, while BTIG initiates on Connect Biopharma (CNTB) with a $10 target. Both firms see strong growth potential in innovative healthcare technologies.